Image source: © Phartisan | Megapixl.com
Highlights
- ResMed offers cloud-connected devices and digital health technologies that treat people with COPD, sleep apnea and other chronic disease outside the hospital
- RMD registered double digit growth in income and revenue during the financial year 2023
- Increased demand for RDM’s products and decreased competitive supply resulted in 23% increase in the company’s June quarter revenue
Medical device manufacturer ResMed Inc. (ASX: RMD) offers innovative solutions that treat people outside the hospital. Cloud-connected devices and digital health technologies assist people with COPD, sleep apnea and other chronic diseases at their homes or setting of their choice. The provider of out-of-hospital software platforms has recorded double-digit growth in income and revenue during the financial year 2023 (FY23).
During the reported period, the company registered 18% year-on-year growth in revenue to USD 4,222.9 million. The net income grew by 15.1% on YoY to USD 897.5 million, and total assets increased by 32.4% to USD 6,751.7 million during the same period. Demand for the RMD’s cloud-connected platform, patient interface and software solutions underpinned the company’s performance in FY23.
Here’s the historical financial trend of RMD-

Recent business update
On 3 August 2023, the company reported revenue of USD 1.1 billion in June 2023 quarter, a 23% increase over the previous corresponding period. During the quarter, its net income increased by 18% YoY to USD 229.7 million. The growth was underpinned by increased demand for RDM’s products and decreased competitive supply.
The company announced a dividend of USD 0.048 per share for the second half of the financial year.. The dividend declared is 9% higher than the previously announced dividend. The dividend’s record date is 17 August 2023, and the pay date is 21 September 2023.
Top 10 shareholders of RMD
The top 10 shareholders of RMD together have around 7.23% of the company’s total shareholding, while the top four have about 4.93% stake. First Sentier Investors (Hong Kong) Limited and Vanguard Investments Australia Ltd. have the highest stake in the company, with a shareholding of approximately 1.66% and 1.25%, respectively.

Outlook
ResMed is focused on growing therapy adherence to enhance quality-of-life and patient outcomes. By 2025, the company targets to help 250 million lives.
Share performance of RMD
RMD shares closed 4.63% down at AUD 27.42 per share on 9 August 2023, with a market capitalisation of AUD 42.28 billion. Including today’s share performance, RMD’s share price dropped by 19.49% in the last 12 months and recorded a fall of 20.17% in the last one month.
The 52-week high of RMD is AUD 36.370 apiece, recorded on 1 May 2023, and the 52-week low is AUD 27.360 apiece, recorded on 8 August 2023.
Worth mentioning here is that RMD’s share price fell by 3.150% on 4 August 2023, when the company released its fourth quarter results.

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, currency, is 9 August 2023. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.